Provided by Tiger Fintech (Singapore) Pte. Ltd.

iTeos Therapeutics

10.09
-0.0038-0.04%
Volume:651.43K
Turnover:6.57M
Market Cap:445.74M
PE:-3.27
High:10.11
Open:10.11
Low:10.08
Close:10.10
Loading ...

iTeos Therapeutics Announces Plan to Wind Down Operations and Explore Asset Sales to Maximize Shareholder Value

Reuters
·
28 May

Major Shareholder Makes Bold Move with iTeos Therapeutics Stock

TIPRANKS
·
17 May

EcoR1 Capital, LLC Reports Acquisition of Common Shares of Iteos Therapeutics Inc

Reuters
·
17 May

Ansbert Gadicke Reports Disposal of Common Shares of Iteos Therapeutics Inc

Reuters
·
16 May

Beneficial Owner MPM BioVentures 2014, L.P. Reports Disposal of Common Shares of Iteos Therapeutics Inc

Reuters
·
16 May

iTeos Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
15 May

iTeos Therapeutics Cut to Market Perform From Outperform by Leerink Partners

Dow Jones
·
14 May

HC Wainwright Downgrades iTeos Therapeutics to Neutral From Buy

MT Newswires Live
·
14 May

iTeos Therapeutics (ITOS) Receives a Buy from Piper Sandler

TIPRANKS
·
14 May

iTeos Therapeutics price target lowered to $13 from $16 at Wells Fargo

TIPRANKS
·
14 May

U.S. RESEARCH ROUNDUP-Fair Issac, First Solar, UnitedHealth

Reuters
·
14 May

Iteos Therapeutics Inc. Files Initial Statement of Beneficial Ownership; EcoR1 Capital, LLC Named as Beneficial Owner

Reuters
·
14 May

iTeos Therapeutics Cut to Neutral From Overweight by JP Morgan

Dow Jones
·
14 May

BUZZ-iTeos rises as it looks to conserve cash after cancer drug setback

Reuters
·
14 May

ITeos Therapeutics Shares Gain as Company Seeks Strategic Alternatives

Dow Jones
·
14 May

iTeos Therapeutics downgraded to Neutral at JPMorgan after TIGIT program ended

TIPRANKS
·
14 May

iTeos Therapeutics downgraded to Neutral from Overweight at JPMorgan

TIPRANKS
·
14 May

British stocks mixed as investors assess US inflation, UK labour market report

Reuters
·
14 May

iTeos Therapeutics Up Over 17%, on Pace for Largest Percent Increase in Over a Year -- Data Talk

Dow Jones
·
13 May

Wedbush Adjusts Price Target on iTeos Therapeutics to $10 From $25, Maintains Outperform Rating

MT Newswires Live
·
13 May